p53 expression by immunohistochemistry is an important determinant of survival in patients with chronic lymphocytic leukemia receiving frontline chemo-immunotherapy.
about
Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies.p53 protein expression independently predicts outcome in patients with lower-risk myelodysplastic syndromes with del(5q).TP53 Staining in Tissue Samples of Chronic Lymphocytic Lymphoma Cases: An Immunohistochemical Survey of 51 CasesFirst-line treatment of chronic lymphocytic leukemia: role of alemtuzumab.Progressive but previously untreated CLL patients with greater array CGH complexity exhibit a less durable response to chemoimmunotherapy.Immunohistochemical evaluation of cell proliferation and apoptosis markers in ovarian surface epithelial cells of cladribine-treated ratsYounger patients with chronic lymphocytic leukemia benefit from rituximab treatment: A single center study in China.Advanced chronic lymphoid leukemia with severe bronchopneumonia: an Autopsy Case Report.Diagnostic techniques and therapeutic challenges in patients with TP53 dysfunctional chronic lymphocytic leukemia.Molecular genetics of high-risk chronic lymphocytic leukemia.How best to manage patients with chronic lymphocytic leuekmia with 17p deletion and/or TP53 mutation?Therapy with the FCR regimen does not overcome chronic lymphocytic leukemia biology: aberrant p53 expression predicts response and survival.
P2860
Q30500362-87FE1BC9-54C9-4DC2-AFF5-555E108AD230Q33695954-87FC9BCD-7B19-403A-8A5B-23A00C59DC94Q33747801-AFD264AD-F08E-4CDF-8562-EEAEEDCFF17FQ33956034-4A920435-E7E7-4F73-971C-8E769EB675CAQ34519192-61624CCD-2A23-4B81-9C54-A2F4F3324A26Q34560328-2BFFB6F0-8B05-4F40-8ACF-726CBB2544CBQ36774671-D374FC7E-292A-4D1B-A190-331D03E89A6CQ36936010-3171ED33-59A3-47DE-B75C-030ABA343C45Q38008448-40E21328-0DA1-4826-8C18-B52AB13D143DQ38065304-5A700439-E836-4DC9-9ABB-CD2DF0B3D24DQ38340201-336DE194-D1DE-4B46-B667-41513B12C0D4Q43287325-D229E552-2B7A-453D-A608-B907FEBA9011
P2860
p53 expression by immunohistochemistry is an important determinant of survival in patients with chronic lymphocytic leukemia receiving frontline chemo-immunotherapy.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
2009年论文
@zh
2009年论文
@zh-cn
name
p53 expression by immunohistoc ...... frontline chemo-immunotherapy.
@ast
p53 expression by immunohistoc ...... frontline chemo-immunotherapy.
@en
type
label
p53 expression by immunohistoc ...... frontline chemo-immunotherapy.
@ast
p53 expression by immunohistoc ...... frontline chemo-immunotherapy.
@en
prefLabel
p53 expression by immunohistoc ...... frontline chemo-immunotherapy.
@ast
p53 expression by immunohistoc ...... frontline chemo-immunotherapy.
@en
P2093
P2860
P50
P921
P1433
P1476
p53 expression by immunohistoc ...... frontline chemo-immunotherapy.
@en
P2093
Constantine Tam
Ellen J Schlette
Joan Admirand
Katherine I Lin
Lynne Abruzzo
P2860
P304
P356
10.1080/10428190903165241
P577
2009-10-01T00:00:00Z